Trial Profile
An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2021
Price :
$35
*
At a glance
- Drugs INCB 59872 (Primary)
- Indications Ewing's sarcoma
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 29 Aug 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 14 Jul 2020 Status changed from recruiting to discontinued.
- 12 Jul 2018 Planned number of patients changed from 42 to 21.